
Celularity (CELU) Stock Forecast & Price Target
Celularity (CELU) Analyst Ratings
Bulls say
Celularity Inc is positioned strongly within the biotechnology sector, particularly through its development of off-the-shelf placental-derived cell therapies that address a range of medical conditions, including cancer and degenerative diseases. The company has demonstrated promising clinical results with its lead product, PDA-002, achieving ulcer closure rates of 42.8% to 53.8% at various time points, which compares favorably to existing FDA-approved treatments such as Dermagraft and Dermapace. Additionally, Celularity's majority revenue generation from its bio-banking segment underpins its financial stability, supporting further investment in innovative therapies and enhancing its growth potential.
Bears say
Celularity Inc. faces significant risks associated with manufacturing failures, which could negatively impact its clinical trials and hinder operations in both the biobanking and degenerative diseases segments. Additionally, the observed decline in NK cell function with age poses a challenge for the effectiveness of their proposed therapies, potentially limiting market opportunities for their age-related conditions. The combination of operational uncertainties and scientific limitations presents a concerning outlook for the company's overall growth and revenue generation potential.
This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.
Celularity (CELU) Analyst Forecast & Price Prediction
Start investing in Celularity (CELU)
Order type
Buy in
Order amount
Est. shares
0 shares